Brivaracetam (BRV) and levetiracetam (LEV) are effective antiepileptic drugs that bind selectively to the synaptic vesicle 2A (SV2A) protein. BRV differs from LEV in preclinical studies in that it exhibits a more potent and complete seizure protection across animal models. We reported previously that an allosteric modulator of the SV2A protein had differential effects on BRV compared with LEV, suggesting that they act at different sites or with different conformations of the The SV2A protein is an integral transmembrane protein expressed in the secretory vesicles of neurons and endocrine cells. 4, 5 It is part of a family of proteins, the major facilitator superfamily (MFS), many of which act as transporters of sugars, amino acids, and other components. Fourteen residues in rat SV2A were identified that affected the binding of racetams to the SV2A protein. 6, 7 Sequence analysis showed that these residues are important in the function of other MFS transporters. We therefore further
| INTRODUCTION
Levetiracetam (LEV) and brivaracetam (BRV) are both racetam-type molecules, which are effective antiepileptic drugs with a unique molecular mechanism. Both drugs target the synaptic vesicle 2A membrane protein (SV2A), although BRV is more selective and has a higher affinity than LEV. 1 However, the precise role of the SV2A protein and the immediate downstream functional consequences of LEV and BRV binding to this protein remain largely unknown. BRV displays both a more potent and complete seizure protection than LEV in animal models of epilepsy. 1 We hypothesized that this differential preclinical profile of BRV and LEV may be due to a differential interaction of BRV and LEV with the SV2A protein. We showed previously that UCB1244283 had a differential effect on the binding of SV2A ligands to the SV2A protein. 2 This compound potentiated the binding of an SV2A ligand by an allosteric mechanism and was therefore described as a modulator. This compound did not compete for the binding of The SV2A protein is an integral transmembrane protein expressed in the secretory vesicles of neurons and endocrine cells. 4, 5 It is part of a family of proteins, the major facilitator superfamily (MFS), many of which act as transporters of sugars, amino acids, and other components. Fourteen residues in rat SV2A were identified that affected the binding of racetams to the SV2A protein. 6, 7 Sequence analysis showed that these residues are important in the function of other MFS transporters. We therefore further hypothesized that mutagenesis of these sites may have a differential effect on the modulation of BRV binding compared with LEV binding to human SV2A. Figure S2 ) were synthesized at UCB BioPharma (Braine-l'Alleud, Belgium). inhibitor cocktail (Roche Diagnostics Belgium, Vilvoorde, Belgium). The homogenate was freeze-thawed twice and equilibrated at 25°C followed by a 10 minute DNAse (10 U mL −1 ) treatment. Subsequently, the solution was centrifuged for 25 minutes at 40 000 g and 4°C. Finally, the pellet was resuspended in buffer at a protein concentration of 5-10 mg mL −1 and stored in liquid nitrogen.
| Membrane preparations

| Radioligand binding studies
Experiments were performed as described previously 3 using saturation binding of Figure 1 ).
| DISCUSSION
The SV2A protein is a therapeutic target for antiepileptic drugs. We have previously suggested that BRV and LEV interact differently with the SV2A protein, based on the differential effect of an SV2A modulator (UCB1244283), which allosterically potentiates the interaction of ligands with the SV2A protein. 2 This modulator increased the binding of BRV, mainly by an increase in affinity, but increased the binding of LEV mainly through an increase in the number of binding sites. 3 This suggests that the modulator induces a conformational change in the SV2A ) in wild-type (A), which was maintained in I273A mutant (B), the potentiation of [3H]LEV binding by the modulator in wild-type (C), and the loss of this effect in I273A mutant (D). Data are from a representative experiment with triplicate determinations; the experiment was repeated with similar results at least twice protein that alters the interaction of BRV and LEV. From this, it is inferred that different amino acids may be involved in this conformational effect, changing the interaction with their recognition sites. Previous studies had proposed a binding site for SV2A racetam ligands, which identified 14 residues, but this used the rat SV2A protein. 6, 7 There is a high sequence homology between rat and human SV2A proteins (Figure S1 8, 9 ), and we have confirmed that many of the residues identified for racetam binding to rat SV2A are also important in the human protein. In the absence of both a functional model for SV2A and an understanding of its physiologic role, it is difficult to determine the impact of the current findings on the therapeutic differences between BRV and LEV. However, the data confirm and extend previous findings suggesting that BRV and LEV interact differently with the SV2A protein and correlate with a more potent and complete seizure suppression by BRV in animal models of genetic and acquired epilepsy. 
